Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This study will examine whether patients with relapsed/refractory solid tumors harboring
evidence of somatic hypermutation (intermediate versus high tumor mutational burden) will
exhibit improvement in disease progression-free survival with dual Tremelimumab and
Durvalumab treatment.